

研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Masaki A, Ishida T , Maeda Y, Suzuki S, Ito A, Takino H, Ogura H, Totani H, Yoshida T, Kinoshita S, Narita T, Ri M, Kusumoto S, Inagaki A, Komatsu H, Niimi A, Ueda R , Utsunomiya A, Inagaki H, Iida S .	Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma.	Clin Cancer Res.		Epub ahead of print	2015
Ishida T , Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R .	Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive ATL: a randomized phase II study.	Br J Haematol.		672-82	2015
Ifuku H, Kusumoto S, Tanaka Y, Totani H, Ishida T , Okada M, Murakami S, Mizokami M, Ueda R , Iida S .	Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.	Hepatol Res.		Epub ahead of print	2015
Totani H, Kusumoto S, Ishida T , Masuda A, Yoshida T, Ito A, Ri M, Komatsu H, Murakami S, Mizokami M, Ueda R , Niimi A, Inagaki H, Tanaka Y, Iida S .	Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy.	Int J Hematol.	101	398-404	2015
Suzuki T, Kusumoto S, Masaki A, Ishida T , Inagaki H, Iida S , Mori F.	CD30-positive primary bone marrow lymphoma mimicking Hodgkin lymphoma.	Int J Hematol.	101	109-11	2015
Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E and Udono H .	Immune-mediated anti-tumor effect by type 2 diabetes drug, metformin.	Pros Natl Acad Sci USA	112	1809-14	2015

Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, Maekawa R, Matsushima K, Ohara O, <u>Kakimi K</u> .	Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFN- γ -dependent cell cycle arrest.	Cancer Immunol Res.	3	26-36	2015
Ueha S, Yokochi S, Ishiwata Y, Ogiwara H, Chand K, Nakajima T, Hachiga K, Shichino S, Terashima Y, Toda E, Shand FH, <u>Kakimi K</u> , Ito S, Matshushima K.	Robust anti-tumor effects of combined anti-CD4 depleting antibody and anti-PD-1/PD-L1 immune checkpoint antibody treatment in mice.	Cancer Immunol Res.	20	Epub ahead of print	2015
Suzuki S, <u>Ishida T</u> , Yoshikawa K, <u>Ueda R</u> .	Progress in clinical use of CCR4 antibody for regulatory T cell suppression.	Inflammation and Immunity in Cancer.		207-27	2015
<u>Ueda R</u> , Suzuki S, Yoshikawa K, <u>Ishida T</u> ;	Clinical application of anti-CCR4 monoclonal antibody. Recent advances in cancer immunotherapy.	Recent advances in cancer immunotherapy		82-7	2014
Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M, Nishio Y, Uenaka A, <u>Oka M</u> and <u>Nakayama E</u>	Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an anti-human CCR4 mAb (KM2760)	J. Thor. Oncol.	10	74-83	2014
Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, Fukuda M, Uenaka A, <u>Oka M</u> and <u>Nakayama E</u> .	Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody.	Clin. Cancer Res	20	5052-63	2014
Ohue Y, <u>Wada H</u> , <u>Oka M</u> and <u>Nakayama E</u>	Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients.	OncoImmunology	3	e970032	2014
Pandey, J, Namboodiri, A, Ohue, Y, <u>Oka, M</u> , <u>Nakayama, E</u> .	Genetic variants of immunoglobulin and chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.	Clin Exp Immunol	176	78-83	2014
Uehara T, Fujiwara T, Takeda K, Kunisada T, Ozaki T, <u>Udono H</u>	Immunotherapy for Bone and Soft Tissue Sarcomas.	BioMed Research International		Article ID 820813	2014

Ichiyanagi T, Ichiyanagi K, Ogawa A, Kuramochi-Miyagawa S, Nakano T, Chuma S, Sasaki H, <u>Udono H</u>	HSP90 plays an important role in piRNA biogenesis and retrotransposon repression in mouse.	Nucleic Acids Res.	42	11903-11	2014
Eikawa S, <u>Udono H</u>	Monitoring multifunctionality of immune-exhausted CD8 T cells in cancer bearing patients.	Methods in Mol Biol.	1142	11-7	2014
<u>Wada H</u> , Isobe M, <u>Kakimi K</u> , Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, <u>Udono H</u> , Seto Y, Yamada K, <u>Nishikawa H</u> , Pan L, Venhaus R, <u>Doki Y</u> , <u>Oka M</u> , <u>Nakayama E</u>	Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing NY-ESO-1 antigen.	J. of Immunotherapy.	37	84-92	2014
Maeda Y, <u>Nishikawa H</u> , Sugiyama D, Ha D, Hamaguchi M, Saito T, Nishioka M, Wing JB, Adeegbe D, Katayama I and Shakaguchi S.	Regulatory T cells drive autoimmune T cells into a distinct T-cell subpopulation functionally anergic and expressing CTLA-4.	Science.	346	1536-40	2014
Matsumoto M, Baba A, Yokota T, <u>Nishikawa H</u> , Ohkawa Y, Kayama H, Kallies A, Nutt SL, Sakaguchi S, Takeda K, Kurosaki T and Baba Y.	Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation.	Immunity	41	1040-51	2014
<u>Nishikawa H</u> , Sakaguchi S	Regulatory T cells in cancer immunotherapy	Curr Opin Immunol.	27	1-7	2014
Ito Y, Hashimoto M, Hirota K, Ohkura N, Morikawa H, <u>Nishikawa H</u> , Tanaka A, Furu M, Ito H, Fujii T, Nomura T, Yamazaki S, Morita A, Vignali DAA, Kappler JW, Matsuda S, Mimori T, Sakaguchi N and Sakaguchi S.	Detection of T-cell responses to a ubiquitous cellular protein in autoimmune disease.	Science.	346	363-8	2014

Saito T, Wada H, Yama saki M, Miyata H, <u>Nishikawa H</u> , Sato E, Kage yama S, Shiku H, Mori M, <u>Doki Y</u> .	High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine	Vaccine	32	5901-7	2014
Mizote Y, Uenaka A, Isobe M, <u>Wada H</u> , <u>Kakimi K</u> , Saika T, Kita S, Koide Y, <u>Oka M</u> , <u>Nakayama E</u>	Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.	Vaccine	32	957-64	2014
Ichimura T, Morikawa T, Kawai T, Nakagawa T, Matsushita H, <u>Kakimi K</u> , Kume H, Ishikawa S, Homma Y, Fukayama M.	Prognostic Significance of CD204-Positive Macrophages in Upper Urinary Tract Cancer	Ann Surg Oncol.	21	2105-12	2014
Wada I, Matsushita H, Noji S, Mori K, Yamas hita H, Nomura S, Shimizu N, Seto Y, <u>Kakimi K</u> .	Intraperitoneal injection of in vitro expanded V γ 9V δ 2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.	Cancer Med.	3	362-75	2014
Hosoi A, Matsushita H, Shimizu K, Fujii S, Ueha S, Abe J, Kurachi M, Maekawa R, Matsushima K, <u>Kakimi K</u> .	Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.	Int J Cancer.	134	1810-22.	2014
Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, <u>Kakimi K</u> .	Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy.	Mol Clin Oncol.	2	1023-27	2014
Matsushita H, Enomoto H, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y and <u>Kakimi K</u> .	A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma.	J Immunother Cancer.	2	30	2014
Futami J, Fujiyama H, Kinoshita R, Nonomura H, Honjo T, Tada H, Matsushita H, Abe Y, <u>Kakimi K</u> .	Denatured mammalian proteins in mixtures exhibit unusually high solubility in nucleic acid-free pure water.	PLoS One.	9	e113295	2014

Kobayashi T, <u>Kakimi K,</u> <u>Nakayama E,</u> Jimbow K.	Antitumor immunity by magnetic nanoparticle-mediated hyperthermia.	Nanomedicine (Lond)	9	1715-26	2014
Ogura M, <u>Ishida T,</u> Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, <u>Ueda R.</u>	Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.	J Clin Oncol.	32	1157-63	2014
Narita T, <u>Ishida T,</u> Masaki A, Suzuki S, Ito A, Mori F, Yamada T, Masaki Ri, Kusumoto S, Komatsu H, Miyazaki Y, Takatsuka Y, Utsunomiya A, Niimi A, <u>Iida S,</u> <u>Ueda R.</u>	HTLV-1 bZIP factor specific CD4 T cell responses in ATL patients after allogeneic hematopoietic stem cell transplantation.	J Immunol.	192	940-7	2014
Mizote Y, Wakamatsu K, Ito S, Uenaka A, Ohue Y, Kurose K, Isobe M, Ito A, Tamura Y, Honda H, Yamashita T, Nohara S, <u>Oka M,</u> Jimbow K, and <u>Nakayama E.</u>	TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteamine-phenol-maleimide-dextran (NPCMD).	J Dermatol Sci,	73	209-15	2014
Mizote Y, Uenaka A, Isobe M, Wada H, <u>Kakimi K,</u> Saika T, Kita S, Koide Y, <u>Oka M,</u> and <u>Nakayama E.</u>	Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.	Vaccine	32	957-64	2014
Wada H, Isobe M, <u>Kakimi K,</u> Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, <u>Udono H,</u> Seto Y, Yamada K, <u>Nishikawa H,</u> Pan L, Venhaus R, <u>Oka M,</u> <u>Doki Y,</u> <u>Nakayama E.</u>	Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.	J Immunother	37	84-92	2014

Nakano N, Kusumoto S, Tanaka Y, <u>Ishida T</u> , T akeuchi S, Takatsuka Y, Akinaga S, Mizokami M, <u>Ueda R</u> , Utsunomiya A.	Utsunomiya A. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.	Hepatol Res.	44	354-7	2014
Mori F, <u>Ishida T</u> , Ito A, Sato F, Masaki A, Narita T, Suzuki S, Yamada T, Takino H, Ri M, Kusumoto S, Komatsu H, Hishizawa M, Imada K, Takaori-Kondo A, Niimi A, <u>Ueda R</u> , Inagaki H, <u>Iida S</u> .	Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model.	Eur J Haematol.	92	219-28	2014
Xia H, Yamada S, Aoyama M, Sato F, Masaki A, Ge Y, Ri M, <u>Ishida T</u> , <u>Ueda R</u> , Utsunomiya A, Asai K, Inagaki H.	Prognostic impact of miR-145 down-regulation in adult T-cell leukemia/lymphoma.	Human Pathol	45	1192-8	2014
Ogura M, <u>Ishida T</u> , Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, <u>Ueda R</u> .	Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.	J Clin Oncol.	32	1157-63	2014
Narita T, <u>Ishida T</u> , Masaki A, Suzuki S, Ito A, Mori F, Yamada T, Masaki Ri, Kusumoto S, Komatsu H, Miyazaki Y, Takatsuka Y, Utsunomiya A, Niimi A, <u>Iida S</u> , <u>Ueda R</u> .	HTLV-1 bZIP factor specific CD4 T cell responses in ATL patients after allogeneic hematopoietic stem cell transplantation.	J Immunol.	192	940-7	2014
Mizote Y, Wakamatsu K, Ito S, Uenaka A, Ohue Y, Kurose K, Isobe M, Ito A, Tamura Y, Honda H, Yamashita T, Nohara S, <u>Oka M</u> , Jimbow K, and <u>Nakayama E</u> .	TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteamine-phenol-maleimide-dextran (NPCMD).	J Dermatol Sci,	73	209-15	2014

Mizote Y, Uenaka A, Isobe M, Wada H, <u>Kakimi K</u> , Saika T, Kita S, Koide Y, <u>Oka M</u> , and <u>Nakayama E</u> .	Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.	Vaccine	32	957-64	2014
Wada H, Isobe M, <u>Kakimi K</u> , Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, <u>Udono H</u> , Seto Y, Yamada K, <u>Nishikawa H</u> , Pan L, Venhaus R, <u>Oka M</u> , <u>Doki Y</u> , <u>Nakayama E</u> .	Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.	J Immunother	37	84-92	2014
<u>Nishikawa H</u> , Sakaguchi S	Regulatory T cells in cancer immunotherapy.	Eur J Haematol.	27	1-7	2014
Mori F, <u>Ishida T</u> , Ito A, Sato F, Masaki A, Narita T, Suzuki S, Yamada T, Takino H, Ri M, Kusumoto S, Komatsu H, Hishizawa M, Imada K, Takaori-Kondo A, Niimi A, <u>Ueda R</u> , Inagaki H, <u>Iida S</u> .	Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model.	Eur J Haematol.	92	219-28	2014
Zwick C, Held G, Auth M, Bernal-Mizrachi L, Roback JD, Sunay S, <u>Iida S</u> , Kuroda Y, Sakai A, Ziepert M, <u>Ueda R</u> , Pfreundschuh M, Preuss K-D.	Over one third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal-dominantly inherited risk factor for MGUS/MM.	Int J Cancer	135	934-8	2014
Nishikawa S, Konno M., Hamabe A., Hasegawa S., Ogawa H., Kano Y., Fukusumi T., Ohta K., Noguchi Y, Ozaki M., Kudo T., Sakai D., Harauchi N., Satoh T., <u>Doki Y.</u> , Mori M. and Ishii.	Aldehyde dehydrogenasehigh gastric cancer stem cells are resistant to chemotherapy.	Int J Oncol	42	1437-42	2014

Ogino T., Nishimura J., Barman S., Kayama H., Uematsu S., Okuzaki D., Osawa H., Haraguchi N., Uemura M., Hata T., Takemasa I., Mizushima T., Yamamoto H., Takeda K., <u>Doki Y.</u> , Mori M.	Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease.	Gastroenterol	145	1380-91	2014
Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, <u>Kakimi K.</u>	Intraperitoneal injection of in vitro expanded V γ 9V δ 2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.	Cancer Med.	3	362-75	2014
Ichimura T, Morikawa T, Kawai T, Nakagawa T, Matsushita H, <u>Kakimi K.</u> , Kume H, Ishikawa S, Homma Y, Fukayama M.	Prognostic Significance of CD204-Positive Macrophages in Upper Urinary Tract Cancer.	Ann Surg Oncol.	21	2105-12	2014
Sugiyama D, <u>Nishikawa H.</u> Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, Karbach J, Jager E and Shakaguchi S	Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking anti-tumor immune responses in humans.	Proc. Natl. Acad Sci USA.	110	17945-50	2013
Ishida T , Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, Eto T, Miyazaki Y, Hidaka M, Uike N, Miyamoto T, Tsudo M, Sakamaki H, Morishima Y, Suzuki R, Utsunomiya A.	Impact of GVHD on allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study Biology of Blood and Marrow Transplantation.	Biol Blood Marrow Transplant.	19	1731-9	2013
Suzuki T, Kusumoto S, Yoshida T, Mori F, Ito A, Ri M, <u>Ishida T.</u> Komatsu H, Niimi A, <u>Iida S.</u>	Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.	Int J Hematol.	97	540-3	2013
Masaki A, <u>Ishida T.</u> Suzuki S, Ito A, Mori F, Sato F, Narita T, Yamada T, Ri M, Kusumoto S, Komatsu H, Tanaka Y, Niimi A, Inagaki H, <u>Iida S.</u> <u>Ueda R.</u>	Autologous Tax-specific CTL therapy in a primary ATL cell-bearing NOD/Shi-scid, IL-2R γ ^{null} mouse model.	J Immunol.	191	135-44	2013

Sato F, <u>Ishida T</u> , Ito A, Mori F, Masaki A, Takino H, Narita T, Ri M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, <u>Ueda R</u> , Inagaki H, <u>Iida S</u> .	Angioimmunoblastic T-cell lymphoma mice model.	Leuk Res.	37	21-27	2013
Inagaki A, Tajima E, Urinishi M, Totani H, Asano Y, Ogura H, Masaki A, Yoshida T, Mori F, Ito A, Yano H, Ri M, Kayukawa S, Kataoka T, Kusumoto S, <u>Ishida T</u> , Hayami Y, Hanamura I, Komatsu H, Inagaki H, Matsuda Y, <u>Ueda R</u> , <u>Iida S</u> .	Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma.	Leuk Res.	37	1648-55	2013
Miyazaki Y, Fujiwara H, Asai H, Ochi F, Ochi T, Azuma T, <u>Ishida T</u> , Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M.	Development of a novel redirected T cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.	Blood	121	4894-901	2013
Kato H, Saito C, Ito E, Furuhashi T, Nishida E, <u>Ishida T</u> , <u>Ueda R</u> , Inagaki H, Morita A.	Bath-PUVA Therapy Decreases Infiltrating CCR4-Expressing Tumor Cells and Regulatory T Cells in Patients With Mycosis Fungoides.	Clin Lymphoma Myeloma Leuk.	13	273-80	2013
<u>Ishida T</u> , Ito A, Sato F, Kusumoto S, <u>Iida S</u> , Inagaki H, Morita A, Akinaga S, Ueda R.	Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.	Cancer Sci.	104	647-50	2013
Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoaka D, Utsumi M, Yasuda Y, <u>Nakayama E</u> , Miyake Y, Ikeda F, Shiraha H, Nouse K, Fujiwara T, and Yamamoto K.	Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?	J Gastroenterol	48	1373-83	2013
Pandey J, Namboodiri A, Ohue Y, <u>Oka M</u> , <u>Nakayama E</u> .	Genetic variants of immunoglobulin and chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.	Clin Exp Immunol	176	78-83	2013

Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, <u>Nakayama E.</u> Ishida T, Obata Y, Carver B, Scher H, Scardino P, Slovin S, Subudhi S K, Reuter VE, Savage C, Allison JP, Melamed JM, J?ger E, Ritter G, Old LJ, Gnjjatic S.	Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein.	Clin Cancer Res	19	6112-25	2013
Ito A, Yamaguchi M, Okamoto N, Sanematsu Y, Kawabe Y, Wakamatsu K, Ito S, Honda H, Kobayashi T, <u>Nakayama E.</u> Tamura Y, Okura M, Yamashita T, Jimbow K, and Kamihira M.	T-cell receptor repertoires of tumor-infiltrating lymphocytes after hyperthermia using functionalized magnetite nanoparticles.	Nanomedicine	8	891-902	2013
Muraoka D, <u>Nishikawa H.</u> Noguchi T, Wang L, Harada N, Guillaume P, Luescher I, Uenaka A, <u>Nakayama E.</u> Old LJ, Kato T, and Shiku H.	Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8+ T cells.	Vaccine	31	2110-8	2013
Jimbow K, Ishii-Osai Y, Ito S, Tamura Y, Ito A, Yoneta A, Kamiya T, Yamashita T, Honda H, Wakamatsu K, Murae K, Nohara S, <u>Nakayama E.</u> Hasegawa T, Yamamoto I, and Kobayashi T.	Melanoma-targeted chemothermotherapy and in situ peptide immunotherapy through HSP production by using melanogenesis substrate, NPrCAP and magnetite nanoparticles.	J. Skin Cancer	2013	Article ID 742925	2013
Fujiwara S, Wada H, Kawada J, Kawabata R, Fujita J, Hirao T, Makari Y, Shibata K, Iijima S, Jungbluth AA, Nakamura Y, Takahashi T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, <u>Nakayama E.</u> Mori M, and <u>Doki Y.</u>	NY-ESO-1 antibody as a novel tumor marker of gastric cancer.	Br. J. Cancer	108	1119-25	2013

Atarashi K, Tanoue T, Suda W, Oshima K, Naganano Y, <u>Nishikawa H</u> , Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Olle B, Sakaguchi S Taniguchi T, Morita H, Hattori M and Honda K	Treg induction by a rationally selected Clostridia cocktail from the human microbiota.	Nature	500	232-6	2013
Hirayama M, <u>Nishikawa H</u> , Nagata Y, Tsuji T, Kato T, Kageyama S, Ueda S, Sugiyama D, Hori S, Sakaguchi S, Ritter G, Old LJ, Gnjaric S, and Shiku H	Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.	Eur J Immunol.	43	989-1000	2013
Adeegbe DO, <u>Nishikawa H</u>	Natural and induced T regulatory cells in cancer.	Frontiers in Immunology.	4	190	2013
Noguchi T, Ritter G, <u>Nishikawa H</u>	Antibody-based therapy in colorectal cancer.	Immunotherapy	5	533-45	2013
Liu B, Ohishi K, Orito Y, Nakamori Y, <u>Nishikawa H</u> , Ino K, Suzuki K, Matsumoto T, Masuya M, Hamada H, Mineno J, Ono R, Nosaka T, Shiku H, Katayama N.	Manipulation of human early T lymphopoiesis by coculture on human bone marrow stromal cells: Potential utility for adoptive immunotherapy.	Exp Hematol.	41	367-76	2013
Suzuki T, Kusumoto S, <u>Iida S</u> , Tada T, Mori F.	Amelanotic malignant melanoma of unknown primary origin metastasizing to the bone marrow: case report and review of the literature.	Int Med.	53	325-28	2013
Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osaka M, Ohnishi M, Harada N, Hishida T, <u>Doki Y</u> , Shiku H.	Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.	J Transl Med.	11	246	2013

Takahashi T, Serada S., Ako M., Fujimoto M., Miyazaki Y., Nakatsuka R., Ikezoe T., Yokoyama A., Taguchi T., Shimada K., Kurokawa Y., Yamasaki M., Miyata H., Nakajima K., Takiguchi S., Mori M., Doki Y. , Naka T., Nishida T.	New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.	Int J Cancer	133	2737-43	2013
Suzuki R., Yamamoto H., Ngan CY., Ohtsuka M., Kitani K., Uemura M., Nishimura J., Takemasa I., Mizushima T., Sekimoto M., Minamoto T., Doki Y. , Mori M.	Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo.	Int J Oncol	43	1447-55	2013
Nagano H., Tomimaru Y., Eguchi H., Hama N., Wada H., Kawamoto K., Kobayashi S., Mori M., Doki Y.	MicroRNA-29a induces resistance to gemcitabine through the Wnt/ β -catenin signaling pathway in pancreatic cancer cells.	Int J Oncol	43	1066-72	2013
Tsujinaka T, Yamamoto K., Fujita J., Endo S., Kawada J., Nakahira S., Shimokawa T., Kobayashi S., Yamasaki M., Akamaru Y., Miyamoto A., Mizushima T., Shimizu J., Umeshita K., Ito T., Doki Y. , Mori M.	Clinical Study Group of Osaka University on Section of Risk Management. Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial.	Lancet	382	1105-12	2013
Iwagami Y., Eguchi H., Nagano H., Akita H., Hama N., Wada H., Kawamoto K., Kobayashi S., Tomokuni A., Tomimaru Y., Mori M., Doki Y.	miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.	Br J Cancer	109	502-11	2013
Sato F, Ishida T. , Ito A, Mori F, Masaki A, Takino H, Narita T, Rii M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, Ueda R. , Inagaki H, Iida S.	Angioimmunoblastic T-cell lymphoma mice model.	Leuk Res.	37	21-27	2013
Ishida T. , Ito A, Sato F, Kusumoto S, Iida S. , Inagaki H, Morita A, Akinaga S, Ueda R.	Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma.	Cancer Sci.	104	647-50	2013

Eikawa, S., Kakimi, K., Isobe, M., Kuzushima, K., Luescher, I., Ohue, Y., Ikeuchi, K., Uenaka, A., Nishikawa, H., Udono, H., Oka M., and Nakayama, E.	Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.	Int. J. Cancer	132	345-54	2013
Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J, Hirao T, Shibata K, Makari Y, Iijima S, Nishikawa H, Jungbluth AA, Nakamura Y, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y.	NY-ESO-1 antibody as a novel tumour marker of gastric cancer.	Br J Cancer	108	1119-25	2013
Hirayama M, Nishikawa H, Nagata Y, Tsujii T, Kato T, Kageyama S, Ueda S, Sugiyama D, Hori S, Sakaguchi S, Ritter G, Old LJ, Gnjatich S, and Shikuh H.	Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.	Eur J Immunol.	43	989-1000	2013
Muraoka D, Nishikawa H, Noguchi T, Wang L, Harada N, Sato E, Luescher I, Nakayama E, Kato T; Hiroshi Shiku H.	Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8+ T cells.	Vaccine.	31	2110-8	2013
Gupta A, Nuber N, Esslinger C, Wittenbrink M, Treder M, Landshammer A, Noguchi T, Kelly M, Gnjatich S, Ritter E, von Boehmer L, Nishikawa H, Shikuh H, Old LJ, Ritter G, Knuth A, and van den Broek M.	A novel human-derived monoclonal antibody against NY-ESO-1 improves the efficacy of chemotherapy.	Cancer Immun.	13	p3	2013
Yamamoto H. Oshiro R., Ohtsuka M., Uemura M., Haraguchi N., Nishimura J., Takemasa I., Mizushima T., Doki Y, Mori M.	Distinct expression of C4.4A in colorectal cancer detected by different antibodies.	Int J Oncol	42	197-201	2013

Kato H, Saito C, Ito E, Furuhashi T, Nishida E, <u>Ishida T</u> , <u>Ueda R</u> , Inagaki H, Morita A.	Bath-PUVA Therapy Decreases Infiltrating CCR4-Expressing Tumor Cells and Regulatory T Cells in Patients With Mycosis Fungoides.	Clin Lymphoma Myeloma Leuk.	13	273-80	2013
Liu B, Ohishi K, Orito Y, Nakamori Y, <u>Nishikawa H</u> , Ino K, Suzuki K, Matsumoto T, Masuya M, Hamada H, Mineno J, Ono R, Nosaka T, Shiku H, Katayama N.	Manipulation of human early T lymphopoiesis by coculture on human bone marrow stromal cells: Potential utility for adoptive immunotherapy.	Exp Hematol.	41	367-76	2013
<u>Ishida T</u> , Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, <u>Ueda R</u> .	Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study.	J Clin Oncol	30	837-42	2012
Suzuki S, Masaki A, <u>Ishida T</u> , Ito A, Mori F, Sato F, Narita T, Ri M, Kusumoto S, Komatsu H, Fukumori Y, <u>Nishikawa H</u> , Tanaka Y, Niimi A, Inagaki H, <u>Iida S</u> , <u>Ueda R</u> .	Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma.	Cancer Sci.	103	1764-73	2012
Mori F, <u>Ishida T</u> , Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, <u>Ueda R</u>	Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model.	Blood Cancer J.		e67	2012
Ohue, Y., Eikawa, S., Okazaki, N., Mizote, Y., Isobe, M., Uenaka, A., Fukuda M., Old, L.J., Oka, M., and <u>Nakayama, E.</u>	Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.	Int. J. Cancer	131	E649-658	2012

Kawada, J., Wada, H., Isobe, M., Gnjatic, S., Nishikawa, Y., Jungbluth, A.A., Okazaki, N., Uenaka, A., Nakamura, Y., Fujiwara, S., Mizuno, N., Saika, T., Ritter, E., Yamasaki, M., Miyata, H., Ritter, G., Murphy, R., Hoffman, E.W., Pan, L., Old, L.J., Doki, Y. , and Nakayama, E.	Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.	Int. J. Cancer	130	584-92	2012
Hiura Y., Takiguchi S., Yamamoto K., Takahashi T., Kurokawa Y., Yamasaki M., Nakajima K., Miyata H., Fujiwara Y., Mori M., Kangawa K., Doki Y	Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer	Cancer	118	4785-94	2012
Motoori M., Yano M., Yasuda T., Miyata H., Peng YF., Yamasaki M., Shiraishi O., Tanaka K., Ishikawa O., Shiozaki H., Doki Y	Relationship between Immunological Parameters and the Severity of Neutropenia and Effect of Enteral Nutrition on Immune Status during Neoadjuvant Chemotherapy	Oncology	83	91-100	2012
Ito S, Nagata Y, Susumu S, Yoneda A, Matsuo M, Yui K, Udono H , Eguchi S, Kanematsu T.	Phenotypic analysis of monocyte-derived dendritic cells loaded with tumor antigen with heat-shock cognate protein-70.	Anticancer Res.	32	4897-904	2012

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
河上 裕、 上田龍三	新たな時代を迎えたがん免疫療法	Immuno-Oncology Frontier,	1	1	2015
西川博憲 、坂口志文	ヒト制御性T細胞の解析	医学のあゆみ	252	69-74	2015
黒瀬浩史、 岡 三喜男 、 中山晋一	抗CCR4抗体の制御性T細胞への影響と臨床応用の可能性	最新医学	70	393-8	2015
西川博憲	Visual View がん免疫療法のメカニズム	Immuno-Oncology Frontier	1	10-3	2015
和田 尚	抗PD-1抗体の泌尿器科疾患、消化器疾患への応用	最新医学	70	421-7	2015

鈴木 進, <u>石田 高司</u> , 吉川 和宏, <u>上田 龍三</u> :	モガムリズマブ	The Frontiers in Life Sciences. 生命科学から創薬へのイノベーション		183-95	2014
<u>上田龍三</u>	第6回モガムリズマブーサムライたちのクスリ (PART II)	Medical AS AHI	12	78-81	2014
黒瀬浩史, <u>岡 三喜男</u> , <u>中山書一</u>	基礎：抗CCR4抗体の制御性T細胞への影響と臨床応用の可能性	最新医学	70	393-8	2014
<u>岡 三喜男</u> , 大植祥弘, 黒瀬浩史, <u>中山書一</u>	特集：これから期待される肺癌診断と治療：抗体免疫療法	呼吸器内科	26	431-7	2014
<u>岡 三喜男</u> , 大植祥弘, 黒瀬浩史, <u>中山書一</u>	がん精巢抗原に対する免疫応答とその臨床的意義	BIO Clinica	30	31-5	2014
杉山大介, <u>西川博嘉</u>	制御性T細胞および免疫チェックポイント分子の解除による抗腫瘍免疫応答増強の可能性	がん分子標的治療	12	84-8	2014
<u>西川博嘉</u>	制御性T細胞とがん免疫療法	臨床血液	55	475-81	2014
柴川伸吾, <u>鶴殿平一郎</u>	T細胞の免疫疲弊と免疫チェックポイント分子	最新医学	70	62-68	2014
和田 尚, <u>中山書一</u>	免疫バイオマーカーと抗腫瘍効果	実験医学増刊	31	204 - 8	2013
和田 尚, <u>中山書一</u>	がん患者における免疫モニタリング 評価法と国際標準化	医学のあゆみ	244	871-77	2013
前田優香, <u>西川博嘉</u>	成人T細胞白血病・リンパ腫における免疫応答	臨床免疫・アレルギー科	59	367-76	2013
杉山大介, <u>西川博嘉</u>	免疫抑制の克服による抗腫瘍免疫応答増強の可能性	医学のあゆみ	246	913-20	2013
西塔拓郎, <u>西川博嘉</u>	Tregs制御による抗腫瘍免疫応答増強の可能性	医学のあゆみ	246	913-20	2013

西岡めぐみ、 西川博嘉	制御性T細胞による抗腫瘍免疫抑制 そのコントロールによる効果的ながん免疫療法の可能性	実験医学	31	1864-72	2013
和田 尚、 中山書一	がん患者における免疫モニタリング 評価法と国際標準化	医学のあゆみ	244	871-7	2013
和田 尚、 中山書一	解説「腫瘍による制御性T細胞の浸潤誘導」	臨床免疫・アレルギー科	59	253-8	2013
西川博嘉 、坂口志文	制御性T細胞の臨床応用への展望	炎症と免疫	21	66-72	2013
西川博嘉 、坂口志文	ヒトにおける制御性T細胞と関連疾患	感染・炎症・免疫	42	20-7	2013
和田 尚、 土岐祐一郎 、 中山書一	免疫増強・制御モニタリングとがんワクチン	日本臨床	70	2183-8	2012
藤原義之、岸健太郎、本告正明、矢野雅彦、石川治、岡田かおる、益澤徹、森正樹、 土岐祐一郎 、吉田浩二、角田卓也、中村祐輔	消化器がんにおけるがんワクチン療法 胃がんに対するがんペプチドワクチン療法	G.I.Research	20	3120-7	2012